Charles Wykoff, MD, PhD
Disclosures: Consultant/Advisor-Acucela, Adverum, Allergan, Apellis, Arctic Vision, Arrowhead, Bausch + Lomb, Bayer, Bionic Vision Technologies, Chengdu Kanghong Biotechnologies (KHB), Clearside Biomedical, DORC, EyePoint, Genentech, Gyroscope, IVERIC Bio, Kato DSRC, Kodiak Sciences, Merck NGM Biopharmaceuticals, Novartis, Novant Health,OccuRx, Ocular Therapeutix, ONL Therapeutics, Opthea, Oxurion (formerly Thrombogenics), Palatin, Pentavision, PolyPhotonix, RecensMedical, Regeneron, RegenXBio, Roche, SAI MedPartners, Takeda, Thea Open Innovation, Verana Health|Speakers Bureau-Regeneron|Stock Ownership-ONL Therapeutix, PolyPhotonix, RecensMedical, Visgenx|Research Grant-Adverum, Aerie Pharmaceuticals, Aldeyra, Alimera Sciences, Apellis, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnologies (KHB), Clearside Biomedical, Gemini Therapeutics, Genentech, Graybug Vision, Gyroscope, IONIS Pharmaceutical, IVERIC Bio, Kodiak Sciences, LMRI, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Opthea, Outlook Therapeutics, Oxurion, Recens Medical, Regeneron, RegenXBio, Roche, SamChunDang Pharm., Santen, Senju, Taiwan Liposome Company, Xbrane BioPharma - 03/01/2021
No Bio Available.